Inicio › Leucemia mielógena aguda › Carolina del Norte › Winston-Salem
Ensayos clínicos de Leucemia mielógena aguda en Winston-Salem, NC
18 estudios para Leucemia mielógena aguda buscan participantes en centros de Winston-Salem y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
ReclutandoFase 2
- Novant Health Forsyth Medical Center, Winston-Salem
- Wake Forest University Health Sciences, Winston-Salem
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
ReclutandoFase 1
- Wake Forest University Health Sciences, Winston-Salem
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
ReclutandoFase 2
- Novant Health Forsyth Medical Center, Winston-Salem
- Wake Forest University Health Sciences, Winston-Salem
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
ReclutandoFase 3
- Novant Health Winston Salem, Winston-Salem
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
ReclutandoFase 2
- Wake Forest University Health Sciences, Winston-Salem
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
ReclutandoFase 2
- Wake Forest University Health Sciences, Winston-Salem
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
ReclutandoFase 2
- Wake Forest University Health Sciences, Winston-Salem
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
ReclutandoFase 3
- Wake Forest University Health Sciences, Winston-Salem
Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax
ReclutandoFase 2
- Atrium Health Wake Forest Baptist Medical Center, Winston-Salem
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
ReclutandoFase 1/2
- Wake Forest University Health Sciences, Winston-Salem
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
ReclutandoFase 1
- Wake Forest University Health Sciences, Winston-Salem
Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML
ReclutandoEstudio observacional
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
ONC-LEUK-2406: The Impact of Systematic Financial Navigation in Acute Myeloid Leukemia
Reclutando
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
ReclutandoFase 2
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers
Reclutando
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Section of Hematology/Oncology, Winston-Salem
The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
ReclutandoEstudio observacional
- Wake Forest Baptist Health, Winston-Salem
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
ReclutandoFase 1/2
- Atrium Wake Forest Baptist Medical Center, Winston-Salem
Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS
ReclutandoFase 1/2
- Novant Health Cancer Institute, Winston-Salem
Más información sobre Leucemia mielógena aguda en MedlinePlus
Ensayos de Leucemia mielógena aguda en otras ciudades
- Houston, TX85 estudios
- New York City, NY51 estudios
- Boston, MA44 estudios
- Seattle, WA41 estudios
- Baldwin Park, CA40 estudios
- Columbus, OH35 estudios
- Philadelphia, PA34 estudios
- Durham, NC33 estudios
- Atlanta, GA31 estudios
- Tampa, FL29 estudios
- Chicago, IL26 estudios
- Portland, OR25 estudios
Otros estudios en Winston-Salem
- Cáncer (todos los tipos)19 estudios
- Mieloma múltiple14 estudios
- Cáncer de seno14 estudios
- Enfermedad cardiovascular14 estudios
- Cáncer de pulmón de células no pequeñas12 estudios
- Enfermedad de obstrucción pulmonar crónica10 estudios
- Cáncer de ovario10 estudios
- Diabetes tipo 29 estudios
- Síndromes mielodisplásicos9 estudios
- Glioblastoma8 estudios
- Leucemia linfocítica crónica8 estudios
- Cáncer de pulmón8 estudios
De ClinicalTrials.gov, datos obtenidos el 6 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.